Tobias Gerhard
Biographic Data
| ID | 5544038 |
|---|---|
| NAME | Tobias Gerhard |
| GIVEN NAMES | Tobias |
| FAMILY NAME | Gerhard |
| SIGNATURE | GERHARD T |
| AFFILIATIONS | Rutgers, the State University of New Jersey |
| ORCID | 0000-0002-8598-5771 |
| VERIFIED | Yes |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 3 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2010 |
| LATEST PUBLICATION YEAR | 2022 |
| H-INDEX | 0 |
Do coronavirus vaccine challenge trials have a distinctive generalisability problem
Notwithstanding the success of conventional field trials for vaccines against COVID-19, human challenge trials (HCTs) that could obtain more information about these and about other vaccines and further strategies against it are about to start in the UK. One critique of COVID-19 HCTs is their distinct paucity of information on crucial population groups. For safety reasons, these HCTs will exclude candidate participants of advanced age or with como…
Premature Mortality Among Adults With Schizophrenia in the United States
In a US national cohort of adults with schizophrenia, excess deaths from cardiovascular and respiratory diseases implicate modifiable cardiovascular risk factors, including especially tobacco use. Excess deaths directly attributable to alcohol or other drugs highlight threats posed by substance abuse. More aggressive identification and management of cardiovascular risk factors, as well as reducing tobacco use and substance abuse, should be leadin…
Assessing Medication Exposures and Outcomes in the Frail Elderly
BACKGROUND: Large administrative datasets such as Medicare and Medicaid claims have much potential utility in clinical and comparative effectiveness (CE) studies. Among their advantages are the inclusion of clinically heterogeneous populations, without exclusions typical in clinical trials; the ability to study extremely large study populations with power to examine differential outcomes across individual drugs, treatment effect modification, and…
No prominent works on this page.
Assessing Medication Exposures and Outcomes in the Frail Elderly
BACKGROUND: Large administrative datasets such as Medicare and Medicaid claims have much potential utility in clinical and comparative effectiveness (CE) studies. Among their advantages are the inclusion of clinically heterogeneous populations, without exclusions typical in clinical trials; the ability to study extremely large study populations with power to examine differential outcomes across individual drugs, treatment effect modification, and…
Premature Mortality Among Adults With Schizophrenia in the United States
In a US national cohort of adults with schizophrenia, excess deaths from cardiovascular and respiratory diseases implicate modifiable cardiovascular risk factors, including especially tobacco use. Excess deaths directly attributable to alcohol or other drugs highlight threats posed by substance abuse. More aggressive identification and management of cardiovascular risk factors, as well as reducing tobacco use and substance abuse, should be leadin…
Do coronavirus vaccine challenge trials have a distinctive generalisability problem
Notwithstanding the success of conventional field trials for vaccines against COVID-19, human challenge trials (HCTs) that could obtain more information about these and about other vaccines and further strategies against it are about to start in the UK. One critique of COVID-19 HCTs is their distinct paucity of information on crucial population groups. For safety reasons, these HCTs will exclude candidate participants of advanced age or with como…
Environmental health (3 works) · Medicine (3 works) · Population (3 works) · Clinical trial (2 works) · Disease (2 works) · Health Systems, Economic Evaluations, Quality of Life (2 works) · 2019-20 coronavirus outbreak (1 work) · Advanced Causal Inference Techniques (1 work) · Bipolar Disorder and Treatment (1 work) · Cause of death (1 work)